Wednesday Dec 4
Medical News Today
Lead attorney in US-based Thalidomide cases responds to recent $81...
Attorneys representing plaintiffs in the US seeking compensation from the manufacturer and distributors of the birth defect-causing drug Thalidomide today lauded a $81 million settlement announced for Australian victims, but said progress for a similar settlement against GlaxoSmithKline and Sanofi-Aventis , does not appear likely without moving to ... (more)
Customer Interaction Solutions
Hagens Berman: Statement of Steve W. Berman, lead attorney in...
Hagens Berman attorneys representing plaintiffs in the US seeking compensation from the manufacturer and distributors of the birth defect-causing drug Thalidomide today lauded a $81 million settlement announced for Australian victims, but said progress for a similar settlement against GlaxoSmithKline and Sanofi-Aventis does not appear likely ... (more)
Holmes Chapel Parish Council fight to save 'vital' AP Club
Clerk of Holmes Chapel Town Council, Nicola Clarke, is one of many stresses the importance of the health and fitness club remaining open HOLMES Chapel Parish Council have taken it into their own hands to save a health and fitness club that has been at the centre of the community for nearly 40 years.
Annals of Internal Medicine
The Consult Guys: A Pain in the Back
Potential Conflicts of Interest: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Bayer, sanofi-aventis; Consultancies: Bristol-Myers Squibb, Bayer, sanofi-aventis.
Kepler Capital Markets Upgrades Sanofi-Aventis to Buy
A number of other analysts have also recently weighed in on SNY. Analysts at Leerink Swann downgraded shares of Sanofi-Aventis from an "outperform" rating to a "market perform" rating in a research note to investors on Friday, October 18th.
Sanofi-Aventis v. Pfizer Inc.
Last week, in Sanofi-Aventis v. Pfizer Inc. , the Federal Circuit affirmed an award of priority to Pfizer by the Board of Patent Appeals and Interferences in an interference involving the cDNA for the human interleukin-13 receptor binding chain .
U.S. heart guidelines may threaten hot new cholesterol drugs
New U.S. guidelines on heart health that favor potent statins may threaten use or even approval of a hot new class of experimental cholesterol drugs that have been billed as revolutionary new treatments with blockbuster sales potential, analysts said on Wednesday.